A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks.
This study is a randomized controlled multicenter clinical trial. Participants who meet the inclusion criteria can be included in this trial after signing informed consent. A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks. Throughout the trial, participants' nucleic acid or antigen results, 25(OH)D concentrations, etc., need to be tested.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
218
Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
This group will not do any intervention
Peking University Third Hospital
Beijing, Beijing Municipality, China
RECRUITINGChange in incidence of laboratory-confirmed (or COVID-19 antibody test) COVID-19 infection
The test will be nucleic acid or antigen testing twice a week for four weeks
Time frame: 4 weeks
The duration of a positive to negative antigen test after infection with COVID-19
Antigen test results were recorded twice a week for four weeks
Time frame: up to 4 weeks
The duration of symptoms in COVID-19 positive participants
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: up to 4 weeks
The proportion of participants whose symptoms of COVID-19 infection were confirmed by antigen testing for more than 7 days
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: 4 weeks
The proportion of asymptomatic COVID-19 infected persons (those who test positive for the etiology of COVID-19 but have no related clinical manifestations)
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.